No Association Between His 447 His Polymorphism of PPARγ Gene and Osteoporosis in Iranian Postmenopausal Women

Authors Information
Article Notes and Dates
To Cite : Sahmani M, Azizi L, Javadi A, Rashvand Z, Abbasi M. et al. No Association Between His 447 His Polymorphism of PPARγ Gene and Osteoporosis in Iranian Postmenopausal Women, Biotech Health Sci. 2017 ;4(2):e13001. doi: 10.5812/bhs.13001.
Abstract
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnote
References
  • 1. Naghshin R, Javadzadeh A, Mousavi SA, Adeli SH, Heydari A. Comparison of the osteoporosis between male smokers with and without chronic obstructive pulmonary disease. Tanaffos. 2004; 3(9): 13-8
  • 2. Malcolm AJ. Metabolic bone disease. Current Diagnostic Pathol. 2002; 8(1): 19-25
  • 3. Larijani B, Resch H, Bonjour JP, Meybodi HA, Tehrani MM. Osteoporosis in Iran, overview and management. Iranian Journal of Public Health. 2007; : 1-3
  • 4. Karunanithi R, Ganesan S, Panicker TM, Korath MP, Jagadeesan K. Assessment of bone mineral density by DXA and the trabecular microarchitecture of the calcaneum by texture analysis in pre- and postmenopausal women in the evaluation of osteoporosis. J Med Phys. 2007; 32(4): 161-8[DOI][PubMed]
  • 5. Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol. 2000; 166(2): 235-45[PubMed]
  • 6. Shi X, Hamrick M, Isales CM. Energy balance, myostatin, and GILZ: factors regulating adipocyte differentiation in belly and bone. PPAR research. 2007;
  • 7. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology. 1999; 140(11): 5060-5[DOI][PubMed]
  • 8. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, et al. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem. 2000; 275(19): 14388-93[PubMed]
  • 9. Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, et al. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone. 2007; 40(1): 149-59[DOI][PubMed]
  • 10. Fournier T, Handschuh K, Tsatsaris V, Evain-Brion D. Involvement of PPARgamma in human trophoblast invasion. Placenta. 2007; 28 Suppl A-81[DOI][PubMed]
  • 11. Du J, Shi H, Lu Y, Du W, Cao Y, Li Q, et al. Tagging single nucleotide polymorphisms in the PPAR-gamma and RXR-alpha gene and type 2 diabetes risk: a case-control study of a Chinese Han population. J Biomed Res. 2011; 25(1): 33-41[DOI][PubMed]
  • 12. Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO. Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril. 2007; 87(4): 862-9[DOI][PubMed]
  • 13. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun. 1999; 260(1): 122-6[DOI][PubMed]
  • 14. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, et al. The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol. 2005; 192(4): 1087-93[DOI][PubMed]
  • 15. Miller PD. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord. 2006; 7(1-2): 75-89[DOI][PubMed]
  • 16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6): 499-502[PubMed]
  • 17. Rhee EJ, Oh KW, Yun EJ, Jung CH, Park CY, Lee WY, et al. The association of Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma gene with serum osteoprotegerin levels in healthy Korean women. Exp Mol Med. 2007; 39(6): 696-704[DOI][PubMed]
  • 18. Wei W, Wang X, Yang M, Smith LC, Dechow PC, Sonoda J, et al. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab. 2010; 11(6): 503-16[DOI][PubMed]
  • 19. Tamaki J, Iki M, Morita A, Ikeda Y, Sato Y, Kajita E, et al. Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study. Osteoporos Int. 2010; 21(2): 321-9[DOI][PubMed]
  • 20. Yue H, He JW, Zhang H, Hu WW, Hu YQ, Li M, et al. No association between polymorphisms of peroxisome [corrected] proliferator-activated receptor-gamma gene and peak bone mineral density variation in Chinese nuclear families. Osteoporos Int. 2010; 21(5): 873-82[DOI][PubMed]
  • 21. Rooki H, Haerian MS, Azimzadeh P, Ebrahimi M, Mirhafez R, Ferns G, et al. Distribution and genotype frequency of the C1431T and pro12ala polymorphisms of the peroxisome proliferator activator receptor gamma gene in an Iranian population. Indian J Hum Genet. 2013; 19(4): 423-9[DOI][PubMed]
  • 22. Cui LH, Shin MH, Chung EK, Lee YH, Kweon SS, Park KS, et al. Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. Osteoporos Int. 2005; 16(12): 1975-81[DOI][PubMed]
  • 23. Hadi M, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc Health Risk Manag. 2008; 4(2): 427
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Biotechnology and Health Sciences accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check